BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38627786)

  • 1. Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting.
    Shi T; Zhu HH
    J Hematol Oncol; 2024 Apr; 17(1):18. PubMed ID: 38627786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Sawyers JD; Jammal NJ; Short NJ; Kantarjian H; Jabbour EJ
    Clin Adv Hematol Oncol; 2023 Feb; 21(2):68-75. PubMed ID: 36780472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.
    Jabbour E; Haddad FG; Short NJ; Kantarjian H
    JAMA Oncol; 2022 Sep; 8(9):1340-1348. PubMed ID: 35834222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
    Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Abou Dalle I; Jabbour E; Short NJ; Ravandi F
    Curr Treat Options Oncol; 2019 Jan; 20(1):4. PubMed ID: 30675645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Short NJ; Kantarjian H; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):61-66. PubMed ID: 34561201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
    Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
    Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
    Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
    J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
    J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era?
    Litzow MR
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):357-360. PubMed ID: 30466747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
    Haddad FG; Kourie HR; Saleh K
    Br J Haematol; 2023 Sep; 202(6):1084-1086. PubMed ID: 37525325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Daily Practice: A Multicenter Experience.
    Tekgündüz E; Göker H; Kaynar L; Sarı İ; Pala Ç; Doğu MH; Öztürk E; Turgut B; Korkmaz S; Tetik A; Büyükaşık Y; Hacıoğlu SK; Bozdağ SC; Özdemir E; Altuntaş F
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):269-74. PubMed ID: 26927932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives.
    Lee HJ; Thompson JE; Wang ES; Wetzler M
    Cancer; 2011 Apr; 117(8):1583-94. PubMed ID: 21472706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens.
    Xiong ZY; Shen YJ; Zhang SZ; Zhu HH
    Hematology; 2024 Dec; 29(1):2335856. PubMed ID: 38581291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Haddad FG; Jabbour E; Short NJ; Jain N; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):271-276. PubMed ID: 38185587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
    Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
    Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
    Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
    Foà R; Bassan R; Vitale A; Elia L; Piciocchi A; Puzzolo MC; Canichella M; Viero P; Ferrara F; Lunghi M; Fabbiano F; Bonifacio M; Fracchiolla N; Di Bartolomeo P; Mancino A; De Propris MS; Vignetti M; Guarini A; Rambaldi A; Chiaretti S;
    N Engl J Med; 2020 Oct; 383(17):1613-1623. PubMed ID: 33085860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.
    Malagola M; Papayannidis C; Baccarani M
    Ann Hematol; 2016 Apr; 95(5):681-93. PubMed ID: 26891878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.